Cemiplimab

證據等級: L5

預測適應症: 10 個

Cemiplimab: From Cutaneous Squamous Cell Carcinoma to Gallbladder Adenosquamous Carcinoma

One-Sentence Summary

Cemiplimab is an anti-PD-1 immune checkpoint inhibitor originally developed for advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer. The TxGNN model's top-ranked prediction for this candidate is gallbladder adenosquamous carcinoma, but this direction is currently supported by 0 clinical trials and 0 publications — it is a pure network-based prediction with no external validation.

Quick Overview

Item	Content
Original Indication	Advanced/metastatic cutaneous squamous cell carcinoma (CSCC); also approved for basal cell carcinoma and NSCLC (based on known drug class information, not present in this evidence pack)
Predicted New Indication	Gallbladder adenosquamous carcinoma
TxGNN Prediction Score	99.99%
Evidence Level	L5
Finland Market Status	Not Marketed (未上市)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this evidence pack. Based on known information, cemiplimab is a fully human IgG4 monoclonal antibody belonging to the anti-PD-1 immune checkpoint inhibitor class. Its efficacy in cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer has been clinically proven and is well established outside this dataset.

Gallbladder adenosquamous carcinoma contains a squamous differentiation component, which in theory could express PD-L1 and thus respond to PD-1 blockade in the same way cemiplimab acts against squamous tumors elsewhere. However, the immuno-oncology evidence base for gallbladder cancer as a whole is weak, and biliary tract tumors are generally considered a low tumor-mutational-burden, poorly immunogenic ("cold") setting compared to skin or lung squamous cancers.

As a result, this mechanistic link should be read as a network-derived hypothesis rather than a validated pharmacological rationale — it is a purely predictive association with no supporting clinical or literature evidence in the current dataset.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Cemiplimab does not currently hold a marketing authorization in Finland (0 licenses on file in this evidence pack). No product name, dosage form, or approved-indication text is available from the Fimea registry for this candidate.

Cytotoxicity

Cemiplimab is an antineoplastic agent (immune checkpoint inhibitor used across multiple carcinomas), so this section applies. No drug-specific toxicity data was returned by DrugBank in this evidence pack; the table below reflects general characteristics of the anti-PD-1 monoclonal antibody class and should be confirmed against the package insert once available.

Item	Content
Cytotoxicity Classification	Immunotherapy (anti-PD-1 immune checkpoint inhibitor) — not a conventional cytotoxic agent
Myelosuppression Risk	Low (checkpoint inhibitors do not directly suppress bone marrow; hematologic irAEs are uncommon)
Emetogenicity Classification	Low (minimal direct emetogenic potential compared to cytotoxic chemotherapy)
Monitoring Items	Baseline and periodic thyroid function, liver function (ALT/AST/bilirubin), renal function, and clinical monitoring for immune-related adverse events (colitis, pneumonitis, dermatitis, endocrinopathies)
Handling Protection	Standard IV infusion precautions for monoclonal antibodies; cytotoxic drug handling regulations (e.g., closed-system transfer devices) are not required as with conventional chemotherapy

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (gallbladder adenosquamous carcinoma) has no supporting clinical trials or literature, and the tumor's immunologically "cold" biology weakens the mechanistic rationale. With no Finland market presence and a TFDA package insert (DG001, blocking) and full MOA record (DG002, high) still outstanding, this candidate cannot advance past model prediction (L5/S0) at this time.

To proceed, the following is needed:

TFDA/Fimea package insert (warnings, contraindications) — currently a blocking data gap
Confirmed full mechanism of action and DrugBank toxicity profile
Preclinical or case-level evidence of PD-L1 expression / immune infiltrate in gallbladder adenosquamous carcinoma
Consider prioritizing rank 4 (external ear basal cell carcinoma) instead, which already has L4 evidence, an S1 decision stage, and one supporting case report, since it extends an indication cemiplimab is already approved for
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.